Sanofi Sponsored ADR Aktie News

CRISPR Therapeutics, Regeneron, and Sanofi all deserve a close look now. These three biotechs have important growth drivers on the market.

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1 -6 Results add to the consistent high efficacy of Beyfortus against medically attended RSV l...

Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2024, under the c...

Sanofi (NASDAQ:SNY ) Q1 2024 Earnings Conference Call April 25, 2024 8:30 AM ET Company Participants Paul Hudson - Chief Executive Officer François-Xavier Roger - Chief Financial Officer Houman Ashrafian - Executive Vice President & Head-Research & Development Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi Thomas Triomphe - Executive Vice President-Vaccines, Sanofi Olivier...

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new drug launches.

Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024 Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIO Vaccines sales up 5.6%, boosted by Beyfortus Consumer Healthcare (CHC) up 9.0%, b...